HCV viral load testing market seen reaching $1.98B by 2030

By AI, Created 4:48 PM UTC, May 18, 2026, /AGP/ – The hepatitis C virus viral load testing market is projected to grow from $1.39 billion in 2025 to $1.48 billion in 2026, with the trend driven by earlier diagnosis, personalized medicine and broader molecular testing. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - HCV viral load testing helps confirm active hepatitis C infection and monitor how patients respond to antiviral treatment. - Faster, more precise testing can support earlier treatment decisions and better therapy adjustments. - The market’s expansion reflects rising demand for diagnostics that fit personalized medicine and decentralized care.

What happened: - The Business Research Company released a 2026 market report on hepatitis C virus viral load testing. - The market was valued at $1.39 billion in 2025 and is projected to reach $1.48 billion in 2026. - The report forecasts the market will reach $1.98 billion by 2030. - The report was published May 15, 2026, in London. - A free sample of the report is available here. - The full report is available here.

The details: - The market is expected to grow at a 7.2% CAGR from 2025 to 2026. - The forecast calls for a 7.4% CAGR through 2030. - Growth drivers include higher global hepatitis C incidence, more awareness of early diagnosis, expanded diagnostic lab infrastructure, nucleic acid amplification technology, and wider access to antiviral drugs. - Future growth is tied to government screening programs, demand for precise viral load monitoring, decentralized testing sites, molecular diagnostic investment, and higher-sensitivity HCV RNA assays. - HCV viral load testing measures the amount of HCV RNA in a patient’s blood. - The test is used to confirm active infection and to monitor antiviral therapy during and after treatment. - Personalized medicine is a major demand driver because viral load results help guide drug choice, dose and treatment duration. - The Personalized Medicine Coalition reported in February 2024 that the US FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - Additional demand is coming from the need for earlier detection and ongoing monitoring of treatment response. - Real-time PCR testing and automated high-throughput platforms are accelerating the diagnostic workflow. - Point-of-care HCV RNA testing is expanding access in decentralized healthcare settings. - Standardization efforts for viral load quantification assays are improving confidence in accuracy and reliability. - North America led the market in 2025 because of established healthcare infrastructure, broad screening programs and advanced research activity. - Asia-Pacific is expected to post the fastest growth over the forecast period because of rising awareness, expanding healthcare infrastructure and higher investment in molecular diagnostics. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The report points to a market moving from basic infection confirmation toward more continuous, personalized monitoring. - Decentralized testing and point-of-care tools could widen access beyond major hospitals and central labs. - The regional split suggests mature markets remain dominant, while newer diagnostics investment is shifting growth toward Asia-Pacific.

What’s next: - Screening expansion and molecular diagnostic investment are likely to remain key market catalysts. - Wider adoption of high-sensitivity RNA assays could support more precise treatment monitoring. - North America and Asia-Pacific will remain the main regions to watch as the market scales through 2030.